Applied DNA to Deploy Linea™ 1.0 COVID-19 Assay for Rapid Detection of New Omicron Subvariant BA.2


– Announcement Follows First Cases of BA.2 Identified in New York State Where the Majority of COVID-19 Testing Clients Reside – – Linea 1.0 Assay’s Unique Double S-gene Target Design Likely Allows for the Identification of Samples that Contain a Mutation Profile Indicative of BA.2 – STONY BROOK, N.Y.–(BUSINESS WIRE)–$APDN #COVID19Testing—Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), intends to deploy its Linea™ 1.0 COVID-19 Assay (the “Linea 1.0 Assay” or the “Assay”), part of ADCL’s Linea COVID-19 diagnostics and testing portfolio, for the rapid detection of samples containing a mutation profile that is indicative of the BA.2 subvariant (BA.2) of Omicron in COVID-19-positive samples. ADCL believes the Linea 1.0 Assay has clinical utility as a genomic surveillance solution to enable public health authorities to detect and assess BA.2 spread via the reflex testing of COVID-19 positive samples with the Linea 1.0 Assay. When used as a reflex test, the Company believes the Linea 1.0 Assay allows for the rapid and inexpensive identification of positive COVID-19 samples that are indicative of BA.2 relative to costly and time-consuming next-generation sequencing. First identified in November 2021, BA.2 is a descendant of the Omicron variant (BA.1) but differs in some of its genetic traits, including certain mutations in the spike protein, which may make it somewhat harder to detect via S-gene target failure (“SGTF”) on certain third-party assays. SGTF was used globally to track the spread and prevalence of the Omicron variant (BA.1). In silico analysis of the BA.2 subvariant conducted by ADCL indicates that BA.2 will likely result in a unique detection signature on the Linea 1.0 Assay that is distinct from BA.1 and other…

Excerpt only …
Source : Applied DNA to Deploy Linea™ 1.0 COVID-19 Assay for Rapid Detection of New Omicron Subvariant BA.2

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.